AccelBio is a pharmaceutical contract research organization (CRO) and diagnostic testing development and point-of-care services company. We provide actionable results for biotechnology programs and pharmaceutical research and discovery with a focus on customized RNA and neurobiology research, as well as immuno-oncology studies. Both non-GLP and GLP studies available. With our expertise in molecular cell biology and animal work, we leverage premier bioassays in multiple formats, including high-throughput screens using chemically unique entities for drug discovery. During COVID19 we applied our RNA expertise to develop novel, rapid high-throughput Viral RNA diagnostic platforms for SARS-CoV-2 detection globally. Our contract services enable the highest quality R&D focused on genetic models and disease pathways. White-glove diagnostic and other pathogen screening services. We contract under CLIA/CLEP and perform high-complexity diagnostic testing.
Looking for a particular AccelBio employee's phone or email?
AccelBio Questions
The AccelBio annual revenue was $4 million in 2026.
Jason Dictenberg is the Chief Executive Officer and Chairman of AccelBio.
2 people are employed at AccelBio.
AccelBio is based in Farmingdale, New York.
The NAICS codes for AccelBio are [541, 5417, 54171, 541714, 54].
The SIC codes for AccelBio are [873, 87].
Top AccelBio Employees
-
Jason Dictenberg
Chief Executive Officer and Chairman at AccelBio
New York, NY, US13 -
Pavel Iserovich
Senior Research Scientist at AccelBio
New York, NY, US25
Related Companies
